Effects of Tyrosine Kinase Inhibitors and CXCR4 Antagonist on Tumor Growth and Angiogenesis in Rat Glioma Model: MRI and Protein Analysis Study-Reference-Cited by-同舟云学术

Effects of Tyrosine Kinase Inhibitors and CXCR4 Antagonist on Tumor Growth and Angiogenesis in Rat Glioma Model: MRI and Protein Analysis Study

Published:2013-12 Issue:6 Volume:6 Page:660-669
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Ali Meser M.,Kumar Sanath,Shankar Adarsh,Varma Nadimpalli R.S.,Iskander A.S.M.,Janic Branislava,Chwang Wilson B.,Jain Rajan,Babajeni-Feremi Abbas,Borin Thaiz F.,Bagher-Ebadian Hassan,Brown Stephen L.,Ewing James R.,Arbab Ali S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference47 articles.

1. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer;Los;Oncologist,2007

2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence;Norden;Neurology,2008

3. Novel anti-angiogenic therapies for malignant gliomas;Norden;Lancet Neurol,2008

4. Emerging antiangiogenic treatments for gliomas—efficacy and safety issues;Dietrich;Curr Opin Neurol,2008

5. Is nitric oxide (NO) the last word in radiosensitization? A review;Oronsky;Transl Oncol,2012

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma;Cancers;2021-06-15

2. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme;European Journal of Pharmacology;2021-04

3. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study;PLOS ONE;2021-02-05

4. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches;Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies;2021

5. Intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies;New Targeting in the Reversal of Resistant Glioblastomas;2021